Daraxonrasib Drug Asset Due Diligence Report 2026

This Daraxonrasib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 3

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Daraxonrasib can convert its Non-degrading molecular glue profile and pan-RAS+PPIA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Daraxonrasib (query alias: daraxonrasib)
Modality / target	Non-degrading molecular glue; pan-RAS+PPIA; RAS(ON) inhibitor
Highest global status	Phase 3
Originator	Revolution Medicines, Inc.
Active developers	Revolution Medicines, Inc., UT MD Anderson Cancer Center, University of Navarra

The MCP disease footprint includes Pancreatic adenocarcinoma metastatic, Pancreatic Ductal Adenocarcinoma, RAS Mutation Non-Small Cell Lung Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07491445	Phase 3	Recruiting	900	Progression free survival (PFS)
NCT07492680	Phase 2	Not yet recruiting	260	Part 1: Number of participants who achieve Objective Response (OR)
NCT07397338	Phase 1/2	Recruiting	370	Number of patients with adverse events (AEs)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer

Phase 3; n=500; evaluation: Positive. Reported fields: mOS(overall population) = 6.7 month ; mOS(overall population) = 13.2 month

Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study.

Phase 3; n=500; evaluation: Positive. Reported fields: mOS = 6.6 month ( 5.4–8.2); mOS = 13.2 month ( 10.0–NE)

Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma

Phase 1/2; n=168; evaluation: Positive. Reported fields: -; TRAE = 96.0 % ; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Daraxonrasib addresses Pancreatic adenocarcinoma metastatic, Pancreatic Ductal Adenocarcinoma, RAS Mutation Non-Small Cell Lung Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Non-degrading molecular glue—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-01-26	MSD ends takeover talks with Revolution Medicines	Phase 3	Financial terms not disclosed
2025-06-24	Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers	Phase 3	US$2,000.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO